Interestingly, the R521K polymorphism of the EGFR gene was associated with a longer progression-free survival in CRC patients treated with cetuximab.19 Therefore, it is perhaps not surprising to see that the patient showed a striking response to a cetuximab plus sunitinib treatment regimen (Figure 4). The gene discussed is EGFR; the disease is colorectal carcinoma.